Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 137

1.

Characterization of neuroblastic tumors using 18F-FDOPA PET.

Lu MY, Liu YL, Chang HH, Jou ST, Yang YL, Lin KH, Lin DT, Lee YL, Lee H, Wu PY, Luo TY, Shen LH, Huang SF, Liao YF, Hsu WM, Tzen KY; National Taiwan University Neuroblastoma Study Group.

J Nucl Med. 2013 Jan;54(1):42-9. doi: 10.2967/jnumed.112.102772. Epub 2012 Dec 4.

PMID:
23213196
[PubMed - indexed for MEDLINE]
Free Article
2.

18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.

Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, Satyamurthy N, Schiepers C, Cloughesy T.

J Nucl Med. 2006 Jun;47(6):904-11.

PMID:
16741298
[PubMed - indexed for MEDLINE]
Free Article
3.

¹²³I-MIBG scintigraphy/SPECT versus ¹⁸F-FDG PET in paediatric neuroblastoma.

Melzer HI, Coppenrath E, Schmid I, Albert MH, von Schweinitz D, Tudball C, Bartenstein P, Pfluger T.

Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1648-58. doi: 10.1007/s00259-011-1843-8. Epub 2011 May 27.

PMID:
21617976
[PubMed - indexed for MEDLINE]
4.

Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.

Binderup T, Knigge U, Loft A, Mortensen J, Pfeifer A, Federspiel B, Hansen CP, Højgaard L, Kjaer A.

J Nucl Med. 2010 May;51(5):704-12. doi: 10.2967/jnumed.109.069765. Epub 2010 Apr 15.

PMID:
20395333
[PubMed - indexed for MEDLINE]
Free Article
5.

The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas.

Taïeb D, Tessonnier L, Sebag F, Niccoli-Sire P, Morange I, Colavolpe C, De Micco C, Barlier A, Palazzo FF, Henry JF, Mundler O.

Clin Endocrinol (Oxf). 2008 Oct;69(4):580-6. doi: 10.1111/j.1365-2265.2008.03257.x. Epub 2008 Apr 3.

PMID:
18394015
[PubMed - indexed for MEDLINE]
6.

Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study.

Piccardo A, Lopci E, Conte M, Garaventa A, Foppiani L, Altrinetti V, Nanni C, Bianchi P, Cistaro A, Sorrentino S, Cabria M, Pession A, Puntoni M, Villavecchia G, Fanti S.

Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):57-71. doi: 10.1007/s00259-011-1938-2. Epub 2011 Sep 20.

PMID:
21932116
[PubMed - indexed for MEDLINE]
7.

Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy.

King KS, Chen CC, Alexopoulos DK, Whatley MA, Reynolds JC, Patronas N, Ling A, Adams KT, Xekouki P, Lando H, Stratakis CA, Pacak K.

J Clin Endocrinol Metab. 2011 Sep;96(9):2779-85. doi: 10.1210/jc.2011-0333. Epub 2011 Jul 13.

PMID:
21752889
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.

Fottner C, Helisch A, Anlauf M, Rossmann H, Musholt TJ, Kreft A, Schadmand-Fischer S, Bartenstein P, Lackner KJ, Klöppel G, Schreckenberger M, Weber MM.

J Clin Endocrinol Metab. 2010 Jun;95(6):2800-10. doi: 10.1210/jc.2009-2352. Epub 2010 Apr 6.

PMID:
20371665
[PubMed - indexed for MEDLINE]
9.

Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?

Montravers F, Grahek D, Kerrou K, Ruszniewski P, de Beco V, Aide N, Gutman F, Grangé JD, Lotz JP, Talbot JN.

J Nucl Med. 2006 Sep;47(9):1455-62.

PMID:
16954553
[PubMed - indexed for MEDLINE]
Free Article
10.

Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma.

Taggart DR, Han MM, Quach A, Groshen S, Ye W, Villablanca JG, Jackson HA, Mari Aparici C, Carlson D, Maris J, Hawkins R, Matthay KK.

J Clin Oncol. 2009 Nov 10;27(32):5343-9. doi: 10.1200/JCO.2008.20.5732. Epub 2009 Oct 5.

PMID:
19805691
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.

Balogova S, Talbot JN, Nataf V, Michaud L, Huchet V, Kerrou K, Montravers F.

Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):943-66. doi: 10.1007/s00259-013-2342-x. Epub 2013 Feb 16. Review.

PMID:
23417499
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Positron emission tomography with [(18)F]FDOPA and [(18)F]FDG in the imaging of small cell lung carcinoma: preliminary results.

Jacob T, Grahek D, Younsi N, Kerrou K, Aide N, Montravers F, Balogova S, Colombet C, De Beco V, Talbot JN.

Eur J Nucl Med Mol Imaging. 2003 Sep;30(9):1266-9. Epub 2003 Jul 10.

PMID:
12856157
[PubMed - indexed for MEDLINE]
13.

18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.

Imani F, Agopian VG, Auerbach MS, Walter MA, Imani F, Benz MR, Dumont RA, Lai CK, Czernin JG, Yeh MW.

J Nucl Med. 2009 Apr;50(4):513-9. doi: 10.2967/jnumed.108.058396. Epub 2009 Mar 16.

PMID:
19289420
[PubMed - indexed for MEDLINE]
Free Article
14.

6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.

Fiebrich HB, Brouwers AH, Kerstens MN, Pijl ME, Kema IP, de Jong JR, Jager PL, Elsinga PH, Dierckx RA, van der Wal JE, Sluiter WJ, de Vries EG, Links TP.

J Clin Endocrinol Metab. 2009 Oct;94(10):3922-30. doi: 10.1210/jc.2009-1054. Epub 2009 Jul 21.

PMID:
19622618
[PubMed - indexed for MEDLINE]
15.

123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma.

Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL.

J Nucl Med. 2009 Aug;50(8):1237-43. doi: 10.2967/jnumed.108.060467. Epub 2009 Jul 17.

PMID:
19617326
[PubMed - indexed for MEDLINE]
Free Article
16.

18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation.

Imperiale A, Rust E, Gabriel S, Detour J, Goichot B, Duclos B, Kurtz JE, Bachellier P, Namer IJ, Taïeb D.

J Nucl Med. 2014 Mar;55(3):367-72. doi: 10.2967/jnumed.113.126896. Epub 2013 Dec 16.

PMID:
24343986
[PubMed - indexed for MEDLINE]
17.

Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.

Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B, Eisenhofer G, Martiniova L, Adams KT, Pacak K.

J Clin Endocrinol Metab. 2009 Dec;94(12):4757-67. doi: 10.1210/jc.2009-1248. Epub 2009 Oct 28.

PMID:
19864450
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas.

Tripathi M, Sharma R, D'Souza M, Jaimini A, Panwar P, Varshney R, Datta A, Kumar N, Garg G, Singh D, Grover RK, Mishra AK, Mondal A.

Clin Nucl Med. 2009 Dec;34(12):878-83. doi: 10.1097/RLU.0b013e3181becfe0.

PMID:
20139821
[PubMed - indexed for MEDLINE]
19.

18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience.

Ledezma CJ, Chen W, Sai V, Freitas B, Cloughesy T, Czernin J, Pope W.

Eur J Radiol. 2009 Aug;71(2):242-8. doi: 10.1016/j.ejrad.2008.04.018. Epub 2008 May 29.

PMID:
18511228
[PubMed - indexed for MEDLINE]
20.

Clinical utility of functional imaging with ¹⁸F-FDOPA in Von Hippel-Lindau syndrome.

Weisbrod AB, Kitano M, Gesuwan K, Millo C, Herscovitch P, Nilubol N, Linehan WM, Kebebew E.

J Clin Endocrinol Metab. 2012 Apr;97(4):E613-7. doi: 10.1210/jc.2011-2626. Epub 2012 Jan 18.

PMID:
22259055
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk